logo
Share SHARE
FONT-SIZE Plus   Neg

MorphoSys And Novozymes Sign Long-Term Alliance On Slonomics Technology

MorphoSys AG (MPSYY.PK) and Novozymes A/S Thursday said they have signed a multi-year licensing and technology transfer agreement. The agreement provides Novozymes with a non-exclusive license to use MorphoSys's proprietary Slonomics technology to develop novel products within the industrial biotechnology sector.

Novozymes becomes the first industrial biotech company to have access to Slonomics technology. Financial details were not disclosed.

Slonomics technology, which comprises patented methods and know-how, advanced materials and robotic equipment, allows combination of building blocks in exactly the preferred order and composition. Researchers can thus create only the desired diversity among a set of enzyme variants, eliminating all the undesired combinations. In a typical scenario, Novozymes' researchers can reduce the number of variants made from millions to ten thousand.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
While buying interest was somewhat subdued, stocks managed to end Tuesday's trading mostly higher. The gains on the day partly offset the steep drop seen in the previous session, although the major averages remain well off their recent highs. Media and entertainment giant Walt Disney Co. said Tuesday that Christine McCarthy, the company's Treasurer for the past 15 years, will succeed James Rasulo as Chief Financial Officer. New Jersey Governor Chris Christie officially kicked off his campaign for president at an event on Tuesday, joining an already crowded Republican field. Speaking at a rally at his former high school in Livingston, New Jersey, Christie declared he is ready to fight for the people of the United States of America.
comments powered by Disqus
Follow RTT